Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 215

1.

EGFR gene gain and PTEN protein expression are favorable prognostic factors in patients with KRAS wild-type metastatic colorectal cancer treated with cetuximab.

Razis E, Pentheroudakis G, Rigakos G, Bobos M, Kouvatseas G, Tzaida O, Makatsoris T, Papakostas P, Bai M, Goussia A, Samantas E, Papamichael D, Romanidou O, Efstratiou I, Tsolaki E, Psyrri A, De Roock W, Bafaloukos D, Klouvas G, Tejpar S, Kalogeras KT, Pectasides D, Fountzilas G.

J Cancer Res Clin Oncol. 2014 May;140(5):737-48. doi: 10.1007/s00432-014-1626-2. Epub 2014 Mar 5.

PMID:
24595598
2.

Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?

Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group.

Genet Med. 2013 Jul;15(7):517-27. doi: 10.1038/gim.2012.184. Epub 2013 Feb 21.

PMID:
23429431
3.

Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.

Laurent-Puig P, Cayre A, Manceau G, Buc E, Bachet JB, Lecomte T, Rougier P, Lievre A, Landi B, Boige V, Ducreux M, Ychou M, Bibeau F, Bouché O, Reid J, Stone S, Penault-Llorca F.

J Clin Oncol. 2009 Dec 10;27(35):5924-30. doi: 10.1200/JCO.2008.21.6796. Epub 2009 Nov 2.

PMID:
19884556
4.

Analysis of KRAS, BRAF, PTEN, IGF1R, EGFR intron 1 CA status in both primary tumors and paired metastases in determining benefit from cetuximab therapy in colon cancer.

Park JH, Han SW, Oh DY, Im SA, Jeong SY, Park KJ, Kim TY, Bang YJ, Park JG.

Cancer Chemother Pharmacol. 2011 Oct;68(4):1045-55. doi: 10.1007/s00280-011-1586-z. Epub 2011 Feb 22.

PMID:
21340604
5.

PTEN gene expression and mutations in the PIK3CA gene as predictors of clinical benefit to anti-epidermal growth factor receptor antibody therapy in patients with KRAS wild-type metastatic colorectal cancer.

Sood A, McClain D, Maitra R, Basu-Mallick A, Seetharam R, Kaubisch A, Rajdev L, Mariadason JM, Tanaka K, Goel S.

Clin Colorectal Cancer. 2012 Jun;11(2):143-50. doi: 10.1016/j.clcc.2011.12.001. Epub 2012 Jan 28.

6.

Impact of KRAS, BRAF, PIK3CA mutations, PTEN, AREG, EREG expression and skin rash in ≥ 2 line cetuximab-based therapy of colorectal cancer patients.

Saridaki Z, Tzardi M, Papadaki C, Sfakianaki M, Pega F, Kalikaki A, Tsakalaki E, Trypaki M, Messaritakis I, Stathopoulos E, Mavroudis D, Georgoulias V, Souglakos J.

PLoS One. 2011 Jan 20;6(1):e15980. doi: 10.1371/journal.pone.0015980.

7.

The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.

Therkildsen C, Bergmann TK, Henrichsen-Schnack T, Ladelund S, Nilbert M.

Acta Oncol. 2014 Jul;53(7):852-64. doi: 10.3109/0284186X.2014.895036. Epub 2014 Mar 25. Review.

PMID:
24666267
8.

Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab.

Tol J, Dijkstra JR, Klomp M, Teerenstra S, Dommerholt M, Vink-Börger ME, van Cleef PH, van Krieken JH, Punt CJ, Nagtegaal ID.

Eur J Cancer. 2010 Jul;46(11):1997-2009. doi: 10.1016/j.ejca.2010.03.036. Epub 2010 Apr 21.

PMID:
20413299
9.

Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.

László L.

Magy Onkol. 2010 Dec;54(4):383-94. doi: 10.1556/MOnkol.54.2010.4.13.

10.

Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab.

Yen LC, Uen YH, Wu DC, Lu CY, Yu FJ, Wu IC, Lin SR, Wang JY.

Ann Surg. 2010 Feb;251(2):254-60. doi: 10.1097/SLA.0b013e3181bc9d96.

PMID:
20010090
11.

Analysis of PTEN, BRAF and PI3K status for determination of benefit from cetuximab therapy in metastatic colorectal cancer patients refractory to chemotherapy with wild-type KRAS.

Tural D, Batur S, Erdamar S, Akar E, Kepil N, Mandel NM, Serdengeçti S.

Tumour Biol. 2014 Feb;35(2):1041-9. doi: 10.1007/s13277-013-1138-8. Epub 2013 Sep 1.

PMID:
23996432
12.

Prognostic Value of BRAF, PI3K, PTEN, EGFR Copy Number, Amphiregulin and Epiregulin Status in Patients with KRAS Codon 12 Wild-Type Metastatic Colorectal Cancer Receiving First-Line Chemotherapy with Anti-EGFR Therapy.

Llovet P, Sastre J, Ortega JS, Bando I, Ferrer M, García-Alfonso P, Donnay O, Carrato A, Jiménez A, Aranda E, León A, Grávalos C, Cámara JC, Feliú J, Sanchíz B, Caldés T, Díaz-Rubio E.

Mol Diagn Ther. 2015 Dec;19(6):397-408. doi: 10.1007/s40291-015-0165-0.

PMID:
26341080
13.

Is there a role for IGF1R and c-MET pathways in resistance to cetuximab in metastatic colorectal cancer?

Inno A, Di Salvatore M, Cenci T, Martini M, Orlandi A, Strippoli A, Ferrara AM, Bagalà C, Cassano A, Larocca LM, Barone C.

Clin Colorectal Cancer. 2011 Dec;10(4):325-32. doi: 10.1016/j.clcc.2011.03.028. Epub 2011 May 11.

PMID:
21729677
14.

Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes.

Pentheroudakis G, Kotoula V, De Roock W, Kouvatseas G, Papakostas P, Makatsoris T, Papamichael D, Xanthakis I, Sgouros J, Televantou D, Kafiri G, Tsamandas AC, Razis E, Galani E, Bafaloukos D, Efstratiou I, Bompolaki I, Pectasides D, Pavlidis N, Tejpar S, Fountzilas G.

BMC Cancer. 2013 Feb 2;13:49. doi: 10.1186/1471-2407-13-49.

15.

PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer.

Loupakis F, Pollina L, Stasi I, Ruzzo A, Scartozzi M, Santini D, Masi G, Graziano F, Cremolini C, Rulli E, Canestrari E, Funel N, Schiavon G, Petrini I, Magnani M, Tonini G, Campani D, Floriani I, Cascinu S, Falcone A.

J Clin Oncol. 2009 Jun 1;27(16):2622-9. doi: 10.1200/JCO.2008.20.2796. Epub 2009 Apr 27.

PMID:
19398573
16.

Clinical usefulness of KRAS, BRAF, and PIK3CA mutations as predictive markers of cetuximab efficacy in irinotecan- and oxaliplatin-refractory Japanese patients with metastatic colorectal cancer.

Soeda H, Shimodaira H, Watanabe M, Suzuki T, Gamoh M, Mori T, Komine K, Iwama N, Kato S, Ishioka C.

Int J Clin Oncol. 2013 Aug;18(4):670-7. doi: 10.1007/s10147-012-0422-8. Epub 2012 May 26.

PMID:
22638623
17.

Overexpression of MET is a new predictive marker for anti-EGFR therapy in metastatic colorectal cancer with wild-type KRAS.

Kishiki T, Ohnishi H, Masaki T, Ohtsuka K, Ohkura Y, Furuse J, Watanabe T, Sugiyama M.

Cancer Chemother Pharmacol. 2014 Apr;73(4):749-57. doi: 10.1007/s00280-014-2401-4. Epub 2014 Feb 6.

18.

Impact of genetic profiles on the efficacy of anti-EGFR antibodies in metastatic colorectal cancer with KRAS mutation.

Kishiki T, Ohnishi H, Masaki T, Ohtsuka K, Ohkura Y, Furuse J, Sugiyama M, Watanabe T.

Oncol Rep. 2014 Jul;32(1):57-64. doi: 10.3892/or.2014.3179. Epub 2014 May 15.

PMID:
24839940
19.

Combined Analysis of EGFR and PTEN Status in Patients With KRAS Wild-Type Metastatic Colorectal Cancer.

Chen Y, Shi Y, Lin J, Ye YB, Wang XJ, Chen G, Guo ZQ.

Medicine (Baltimore). 2015 Oct;94(40):e1698. doi: 10.1097/MD.0000000000001698.

20.

Combined assessment of epidermal [corrected] growth factor receptor dual color in situ hybridization and immunohistochemistry with downstream gene mutations in prediction of response to the anti-EGFR therapy for patients with metastatic colorectal cancer.

Takahashi N, Yamada Y, Taniguchi H, Honma Y, Iwasa S, Kato K, Hamaguchi T, Shimada Y.

Arch Med Res. 2014 Jul;45(5):366-74. doi: 10.1016/j.arcmed.2014.05.004. Epub 2014 May 13. Erratum in: Arch Med Res. 2014 Aug;45(6):515.

PMID:
24830936

Supplemental Content

Support Center